Latest Stock Buy or Sell?
Make More Informed Decisions!

He is not hopeful. There is a downtrend line that it is running into from below. If we broke $1.13, from current levels then there more to this story than we know. Since Jun/18, its performance against the S&P has been terrible.

This should be going up as with other stocks in this sector. If it is not, then you should own something else. There was a bottom in May that we tested, so that is positive. The relative strength vs. the index is not good.

He got rid of his in one portfolio and has it in another. It has come back to a holding level. It is trying to turn up against the S&P. This would be a place to scale in, but it is very volatile. $431 is a stop level. Make sure it holds.

$64.70 is a low from late August and a bit lower in April. It held in there. Around $69 there is a bunch of resistance. It has had no strength against the S&P since June. We are probably going to come back to the low $60s test.

They are fantastic asset managers. It has a great long term trend. You could buy a half position, knowing you might have to buy the rest lower. It has been a good position.

The downside is better encapsulated here than when he first recommended it in March. It is a really good entry point. They have a fantastic balance sheet. (Analysts’ price target is $37.31)

They are a provider of sequencing solutions for genetic analysis. It is a really good entry level. It is a pretty volatile stock. Commercial genetic testing is going to explode and these guys are emphasizing consumables. (Analysts’ price target is $321.79)

It is trading at a really good level. The risk/reward is pretty good. Their compounding growth had been lacking compared to earlier periods but right now everything is lined up. (Analysts’ price target is $752.89)

European central banks easing again. Easier for banks to lend money over there. The US economy is a better place to be than in Europe. European growth is much more sluggish than US. Though US growth is slowing, it is still growing. Plus, the US consumer is healthier.

TSX flirted with a new high. Sentiment is more positive on trade. The US index is also within spitting distance of a new high. The market reacts positively or negatively, depending on trade news. Expect more volatility until things get resolved. Try to ignore all the noise. The US economy is not as strong as earlier, but the good thing for the US and Canada is that we're seeing consumer spending kick in.

Bond market's wild ride. It has whipsawed, but it has come back from last year. Conveys slower growth. Cash flow is coming into the US from elsewhere, because of negative interest rates abroad, and this drives down US bond yields.

BOC saying we can go it alone on interest rates. Not sure we can do this, as Canada's economy is very tied to the US. BOC is aware of trade tensions. We've seen stronger than expected GDP number in Canada. Employment here is still pretty good.

For new money, waiting for a pullback. Great long-term hold. Likes the space of alternative asset managers, it's growing. They compete globally. Likes management team. Have cash on hand to take advantage of buying assets during any downturn. Yield is 1.2%.

Has gone through a lot. Cut dividend to almost zero. Criticized for past acquisitions. Now need to sell off assets and refocus, and they've done that. Chart reflects what's gone on in energy patch. She doesn't have any energy exposure now.

Bit of a pullback. She is keenly aware of valuation of what she buys. Valuation is very high, and hard to calculate it on a stock like this. Too much momentum driven. Wouldn't be a buyer. PEG ratio of 13 is very high even for a growth stock.